Quality control of prostate 1H MRSI data

NMR in Biomedicine

Volumn 26, Issue 2, 2013, Pages 193-203

  Wright, Alan J ^a   Kobus, Thiele ^a   Selnæs, Kirsten M ^b   Gribbestad, Ingrid S ^b,c   Weiland, Elizabeth ^d   Scheenen, Tom W J ^a   Heerschap, Arend ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d SIEMENS AG   (Germany)

Author keywords

MRSI; Pattern recognition; Prostate cancer; Quality control

Indexed keywords

CLINICAL TOOLS; CLINICAL USE; DATA SETS; GOLD STANDARDS; MRSI; PROSTATE CANCERS; SIGNAL CONTAMINATION; SIGNAL TO NOISE; SPECTRAL PROFILE;

ALGORITHMS; DISEASES; PATTERN RECOGNITION; QUALITY ASSURANCE; UROLOGY;

QUALITY CONTROL;

ARTICLE; CLINICAL ARTICLE; CONSENSUS; GOLD STANDARD; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; RADIOLOGIST; SENSITIVITY AND SPECIFICITY;

ALGORITHMS; EUROPE; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PATTERN RECOGNITION, AUTOMATED; PROTONS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84872620861     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2835     Document Type: Article

References (32)

1. Vilanova JC, Barcelo J. Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging. Abdom. Imaging 2007; 32(2): 253-261.
2. Scheenen TW, Futterer J, Weiland E, van Hecke P, Lemort M, Zechmann C, Schlemmer HP, Broome D, Villeirs G, Lu J, Barentsz J, Roell S, Heerschap A. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest. Radiol. 2011; 46(1): 25-33.
3. Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the prostate. Magn. Reson. Imaging Clin. North Am. 2008; 16(4): 697-710, ix-x.
4. Zhang J, Hricak H, Shukla-Dave A, Akin O, Ishill NM, Carlino LJ, Reuter VE, Eastham JA. Clinical stage T1c prostate cancer: evaluation with endorectal MR imaging and MR spectroscopic imaging. Radiology 2009; 253(2): 425-434.
5. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat. Rev. Cancer 2011; 11(12): 835-848.
6. 1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization. Cancer Biomark. 2008; 4(4-5): 263-276.
7. Futterer JJ, Scheenen TW, Heijmink SW, Huisman HJ, Hulsbergen-Van de Kaa CA, Witjes JA, Heerschap A, Barentsz JO. Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate. Invest. Radiol. 2007; 42(2): 116-122.
8. Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL. Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines. Radiology 2007; 245(2): 499-506.
9. Kobus T, Hambrock T, Hulsbergen-van de Kaa CA, Wright AJ, Barentsz JO, Heerschap A, Scheenen TW. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3T with an endorectal coil. Eur. Urol. 2011; 60(5): 1074-1080.
10. Pels P, Ozturk-Isik E, Swanson MG, Vanhamme L, Kurhanewicz J, Nelson SJ, Van Huffel S. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed. 2006; 19(2): 188-197.
11. Garcia-Martin ML, Adrados M, Ortega MP, Fernandez Gonzalez I, Lopez-Larrubia P, Viano J, Garcia-Segura JM. Quantitative (1)H MR spectroscopic imaging of the prostate gland using LCModel and a dedicated basis-set: correlation with histologic findings. Magn. Reson. Med. 2011; 65(2): 329-339.
12. McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, Sala E. Prostate cancer metabolite quantification relative to water in (1)H-MRSI in vivo at 3 Tesla. Magn. Reson. Med. 2011; 65(4): 914-919.
13. Verma S, Rajesh A, Futterer JJ, Turkbey B, Scheenen TW, Pang Y, Choyke PL, Kurhanewicz J. Prostate MRI and 3D MR spectroscopy: how we do it. AJR Am. J. Roentgenol. 2010; 194(6): 1414-1426.
14. Kelm BM, Menze BH, Zechmann CM, Baudendistel KT, Hamprecht FA. Automated estimation of tumor probability in prostate magnetic resonance spectroscopic imaging: pattern recognition vs quantification. Magn. Reson. Med. 2007; 57(1): 150-159.
15. Weiland E, Scheenen T, Roell S, van Hecke P, Lemort M, Bachert P, Schlemmer H-P, Lu J, Broom D, Villeirs G, Futterer J, Barentsz J, Heerschap A, Proceedings of the 15th Annual Meeting ISMRM, Berlin, Germany, 2007; 200.
16. Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, Barentsz JO, Heerschap A. Three-dimensional proton MR spectroscopy of human prostate at 3T without endorectal coil: feasibility. Radiology, 2007; 245(2): 507-516.
17. de Edelenyi FS, Simonetti AW, Postma G, Huo R, Buydens LMC. Application of independent component analysis to H-1 MR spectroscopic imaging exams of brain tumours. Anal. Chim. Acta 2005; 544(1-2): 36-46.
18. Ladroue C, Howe FA, Griffiths JR, Tate AR. Independent component analysis for automated decomposition of in vivo magnetic resonance spectra. Magn. Reson. Med. 2003; 50(4): 697-703.
19. Wright AJ, Arus C, Wijnen JP, Moreno-Torres A, Griffiths JR, Celda B, Howe FA. Automated quality control protocol for MR spectra of brain tumors. Magn. Reson. Med. 2008; 59(6): 1274-1281.
20. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn. Reson. Med. 2004; 52(1): 80-88.
21. Mescher M, Tannus A, Johnson MO, Garwood M. Solvent suppression using selective echo dephasing. J. Magn. Reson. Ser. A 1996; 123(2): 226-229.
22. Hyvarinen A. Fast and robust fixed-point algorithms for independent component analysis. IEEE Trans. Neural Networks 1999; 10(3): 626-634.
23. Wright AJ, Fellows G, Byrnes TJ, Opstad KS, McIntyre DJ, Griffiths JR, Bell BA, Clark CA, Barrick TR, Howe FA. Pattern recognition of MRSI data shows regions of glioma growth that agree with DTI markers of brain tumor infiltration. Magn. Reson. Med. 2009; 62(6): 1646-1651.
24. LS-SVM Laboratory. LS-SVM algorithm. K. U. Leuven ESAT, SCD-SISTA Division: Leuven. Available at: http://www.esat.kuleuven.ac.be/sista/lssvmlab [accessed 1 March 2011].
25. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 1993; 30(6): 672-679.
26. Wright AJ, Buydens LM, Heerschap A. A phase and frequency alignment protocol for (1)H MRSI data of the prostate. NMR Biomed. 2011; 25(5): 755-765.
27. Laudadio T, Pels P, De Lathauwer L, Van Hecke P, Van Huffel S. Tissue segmentation and classification of MRSI data using canonical correlation analysis. Magn. Reson. Med. 2005; 54(6): 1519-1529.
28. Poullet JB, Sima DM, Van Huffel S. MRS signal quantitation: a review of time- and frequency-domain methods. J. Magn. Reson. 2008; 195(2): 134-144.
29. Wright AJ, Heerschap A. Simple baseline correction for (1)H MRSI data of the prostate. Magn. Reson. Med. 2012; http://dx.doi.org/10.1002/mrm.24182.
30. van der Graaf M, Heerschap A. Effect of cation binding on the proton chemical shifts and the spin-spin coupling constant of citrate. J. Magn. Reson. 1996; 112(1): 58-62.
31. Hyvärinen A, Särelä J, Vigário R. Spikes and bumps: artefacts generated by independent component analysis with insufficient sample size. Proceedings of the International Workshop on Independent Component Analysis and Signal Separation (ICA'99), Alois, France, 1999; 425-429.
32. Vapnik VN. An overview of statistical learning theory. IEEE Trans. Neural Networks 1999; 10(5): 988-999.